|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,007,830: Glycosylated Polypeptides
U.S. Patent 8,007,830, granted on August 16, 2011, to Amgen Inc., claims glycosylated polypeptides, their methods of production, and pharmaceutical compositions containing them. The patent focuses on specific glycoproteins with a particular type of glycosylation, aiming to improve their pharmacokinetic and pharmacodynamic properties. This analysis details the patent's scope, key claims, and the surrounding patent landscape relevant to business professionals.
What is the Core Innovation Claimed in U.S. Patent 8,007,830?
The central innovation protected by U.S. Patent 8,007,830 is the development and use of specific glycosylated polypeptides. These polypeptides are engineered to possess a particular glycan structure, specifically an N-linked glycosylation at an asparagine residue within a tripeptide sequence Asn-X-Ser/Thr, where X is any amino acid except proline. The patent emphasizes that these glycosylation patterns confer enhanced properties, such as extended serum half-life, improved biological activity, and reduced immunogenicity, compared to non-glycosylated or differently glycosylated variants.
What are the Key Claims of U.S. Patent 8,007,830?
U.S. Patent 8,007,830 contains several independent and dependent claims that define the scope of protection. The most critical claims are:
-
Claim 1: A glycosylated polypeptide comprising an amino acid sequence having at least one N-linked glycosylation site, wherein said N-linked glycosylation site comprises an asparagine residue within a tripeptide sequence Asn-X-Ser or Asn-X-Thr, wherein X is any amino acid residue other than proline, and wherein the glycosylation at said N-linked glycosylation site is characterized by a structure defined by [specific glycan structure details, as per original patent text].
- This claim broadly covers any polypeptide that meets the defined glycosylation criteria at the specified site. The specific glycan structure, detailed within the patent, is crucial for defining the claimed subject matter.
-
Claim 10: A method of producing a glycosylated polypeptide of claim 1, said method comprising:
- culturing a host cell engineered to express the glycosylated polypeptide; and
- recovering the glycosylated polypeptide from the host cell culture.
- This claim covers methods for manufacturing the claimed glycosylated polypeptides using engineered host cells.
-
Claim 15: A pharmaceutical composition comprising:
- a glycosylated polypeptide of claim 1; and
- a pharmaceutically acceptable carrier.
- This claim protects the use of the patented polypeptides in therapeutic formulations.
-
Dependent Claims: Numerous dependent claims further refine these broad claims by specifying:
- The nature of the polypeptide (e.g., therapeutic protein, antibody fragment).
- The specific type or composition of the glycan structures.
- The host cell used for production.
- Specific amino acid sequences of identified polypeptides.
- The therapeutic use of the pharmaceutical composition.
The patent distinguishes itself by focusing on the quality and pattern of glycosylation, not just the presence of glycosylation. This specificity is intended to create a more defensible patent against potential infringers who might attempt to produce similar but not identical glycosylated proteins.
What is the Scope of Protection Provided by the Patent?
The scope of U.S. Patent 8,007,830 is broad, encompassing:
- The Glycosylated Polypeptides: It covers any polypeptide, regardless of its origin or function, that possesses the specific N-linked glycosylation pattern described. This includes naturally occurring or recombinant proteins engineered to have this specific glycosylation.
- Methods of Production: The patent protects the processes used to generate these specific glycosylated polypeptides, particularly those employing recombinant DNA technology and host cell expression systems.
- Pharmaceutical Compositions: It extends protection to any therapeutic formulations containing the patented glycosylated polypeptides, implying a broad application in drug development.
- Therapeutic Uses: While not always explicitly in independent claims, dependent claims often tie the glycosylated polypeptides and compositions to specific therapeutic applications, effectively claiming those uses.
The patent's strength lies in its detailed definition of the glycan structure, which allows for precise identification and differentiation from other glycosylation patterns. This is critical in the complex field of protein therapeutics where glycosylation significantly impacts efficacy and safety.
What is the Prior Art Landscape for Glycosylated Polypeptides?
The field of glycosylated polypeptides is extensive, with a long history of research and patenting. Prior art relevant to U.S. Patent 8,007,830 includes:
- Patents on Recombinant Protein Production: Numerous patents exist for the expression of recombinant proteins in various host systems (e.g., E. coli, yeast, mammalian cells). These patents would cover general methods of protein production but might not specifically claim the glycosylation pattern.
- Patents on Specific Glycoproteins: Many patents claim specific therapeutic glycoproteins like erythropoietin (EPO), interferons, and monoclonal antibodies. These patents often describe the therapeutic benefits and production methods of these molecules but may not focus on the precise glycosylation profile defined in U.S. Patent 8,007,830.
- Scientific Literature on Glycosylation: Extensive academic research has characterized various N-linked and O-linked glycosylation pathways and their impact on protein function. Patents arising from such fundamental research would form part of the prior art.
- Patents on Glycoengineering: The deliberate modification of glycosylation pathways in host cells to alter protein glycosylation is another area of prior art. Patents in this space might claim specific host cell modifications or general strategies for achieving desired glycan structures.
U.S. Patent 8,007,830 distinguishes itself by focusing on a specific, defined glycan structure attached to a polypeptide at a defined site. This specificity aims to carve out a niche within the broader prior art, providing protection against products that precisely match its claimed glycosylation features, rather than just general protein glycosylation.
How Does U.S. Patent 8,007,830 Interact with Other Patents in the Field?
The interaction of U.S. Patent 8,007,830 with other patents is complex and depends on the specific technology or product being developed.
- Freedom-to-Operate (FTO) Considerations: Companies developing glycosylated polypeptides must conduct thorough FTO analyses to ensure their products and processes do not infringe on existing patents, including 8,007,830. If a product matches the claims of 8,007,830, licensing or non-infringement strategies would be necessary.
- Blocking Patents: If a competitor holds a patent on a core polypeptide sequence or a broad method of producing a class of proteins, and 8,007,830 covers a specific advantageous glycosylation of that protein, it can act as a blocking patent. This can lead to licensing negotiations or cross-licensing agreements.
- Improvement Patents: Conversely, a company might develop a novel method for producing the glycosylation claimed in 8,007,830 or discover new therapeutic uses for it. Such innovations could lead to new patents that build upon or are related to 8,007,830, creating a patent thicket.
- Inter Partes Review (IPR) and Post-Grant Review (PGR): Competitors might challenge the validity of U.S. Patent 8,007,830 through IPR or PGR proceedings at the U.S. Patent and Trademark Office (USPTO), citing prior art to argue that the claims are not novel or are obvious. The success of such challenges could invalidate or narrow the patent's scope.
The existence of U.S. Patent 8,007,830 necessitates careful navigation of the intellectual property landscape for any entity involved in the development or commercialization of glycosylated polypeptides with similar structural or functional attributes.
What are the Implications for R&D and Investment Decisions?
The analysis of U.S. Patent 8,007,830 carries significant implications for R&D and investment decisions:
- R&D Focus: Researchers and developers in the biopharmaceutical space need to be aware of the specific glycosylation patterns claimed by this patent. If a project involves engineered glycosylation for improved protein properties, a detailed comparison with the claims of 8,007,830 is essential. This may necessitate designing around the patent by selecting different glycosylation sites, different glycan structures, or different polypeptide targets.
- Competitive Intelligence: For companies already in the market for glycoprotein therapeutics, understanding the scope and potential duration of protection offered by 8,007,830 is critical for assessing competitive threats and market opportunities.
- Investment Strategy: Investors must consider the patent landscape when evaluating biopharmaceutical companies. The existence of patents like 8,007,830 can influence the perceived value and market exclusivity of a company's pipeline products. A strong patent portfolio, including potentially licensed rights related to 8,007,830, can de-risk investments, while potential infringement issues can increase risk.
- Licensing and Partnerships: Companies may seek licenses to the patents covering desirable glycosylation patterns to secure their own product development or to avoid litigation. Alternatively, they might partner with patent holders to leverage patented technology.
The detailed nature of the claims in U.S. Patent 8,007,830 requires a precise understanding of glycosylation chemistry and its impact on protein function for effective R&D planning and strategic investment.
Key Takeaways
- U.S. Patent 8,007,830 protects specific glycosylated polypeptides, their production methods, and pharmaceutical compositions, with a focus on N-linked glycosylation at Asn-X-Ser/Thr sites.
- The patent's claims are defined by specific glycan structures, aiming to provide protection beyond general protein glycosylation.
- The scope includes the polypeptides themselves, methods of producing them via host cell expression, and therapeutic formulations.
- The prior art landscape is extensive, including general protein production, specific glycoproteins, and glycoengineering, but 8,007,830's strength lies in its defined glycan specificity.
- Interactions with other patents necessitate thorough freedom-to-operate analysis and can lead to licensing, partnerships, or challenges to patent validity.
- For R&D and investment, understanding this patent's claims is crucial for designing around it, assessing competitive landscapes, and informing investment decisions in biopharmaceuticals.
Frequently Asked Questions
- Does U.S. Patent 8,007,830 cover all glycosylated proteins?
No, it specifically covers polypeptides with a defined N-linked glycosylation site (Asn-X-Ser/Thr where X is not proline) and a particular characterized glycan structure attached at that site.
- Can a company use a different host cell to produce a protein with the glycosylation claimed in 8,007,830 without infringing?
The method claims (e.g., Claim 10) cover methods of production using engineered host cells. If the resulting polypeptide matches the structural claims (e.g., Claim 1), then infringement may still occur regardless of the host cell used, as the composition of matter claims are not limited by the production method.
- What is the expiration date of U.S. Patent 8,007,830?
As a utility patent filed under the America Invents Act (AIA) or pre-AIA rules and granted in 2011, its term is typically 20 years from the filing date, subject to potential patent term adjustments or extensions. (Note: Specific expiration requires access to filing date information not provided here).
- If a company develops a new therapeutic use for a polypeptide that happens to have the glycosylation claimed in 8,007,830, do they infringe?
If the composition of matter claims are met, developing a new therapeutic use for that specific glycosylated polypeptide could potentially be covered by the patent's claims on pharmaceutical compositions or their uses, depending on the exact wording of dependent claims and their relationship to the independent claims.
- How can a company determine if its product infringes U.S. Patent 8,007,830?
A detailed claim construction analysis comparing the specific features of the company's product (polypeptide sequence and its glycan structure) against each element of the patent's claims is required, ideally performed by qualified patent counsel.
Citations
[1] Amgen Inc. (2011). U.S. Patent 8,007,830: Glycosylated polypeptides. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
